April 21, 2026 1:37pm
Dr. Christopher J. Schaber outlines strategies for navigating constrained funding environment Soligenix (NASDAQ: SNGX) CEO Dr. Christopher J. Schaber emphasized the importance of capital discipline in a Pharmaphorum analysis examining how biotech companies can succeed in today’s constrained funding environment, where even late-stage programs may struggle to secure investment. The article notes that strong science alone is no longer sufficient, […]
April 21, 2026 8:00am
Solana and the rest of the crypto market has gone through many ups and downs over the last few years. The current volatility and pressures in the market, encouraged by ongoing geopolitical factors, have led to attractive entry prices for those looking to get involved with crypto. Current prices, along with growing concern about the […]
April 20, 2026 2:13pm
Channelchek, a Noble Financial Group platform, highlights a changing investment landscape in 2025, where capital is increasingly rotating toward differentiated growth opportunities beyond crowded sectors. Within this environment, Enhanced Group Inc.—an emerging sports, media, and consumer health company—is pursuing a public market debut through a proposed business combination with A Paradise Acquisition Corp. (NASDAQ: APAD), positioning itself within […]
April 20, 2026 2:12pm
NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s […]
April 20, 2026 2:01pm
This article has been disseminated on behalf of Planet Ventures Inc. and may include paid advertising. Planet Ventures (CSE: PXI) (OTC Pink: PNXPF) (FSE: P6U) announced it has adopted a Disclosure, Confidentiality and Insider Trading Policy to strengthen compliance with Canadian securities laws, prevent selective disclosure and ensure proper handling of material information, while also updating its Investment Policy to […]
April 20, 2026 12:00pm
By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that […]
April 20, 2026 8:00am
Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, is advancing its strategy to embed mortgage and title services directly into digital real estate platforms, with a newly announced partnership with Structured Real Estate Group (“SRG”). The agreement, detailed in a company press release, positions Beeline’s technology […]
April 20, 2026 8:00am
Safe Pro Group (NASDAQ: SPAI) reported continued execution of its share repurchase program, with 400,000 shares repurchased as of April 17, 2026, representing approximately 3.5% of its public float under a $3.0 million authorization approved in December 2025. The company funded repurchases through operating cash flow and its strong balance sheet, which included $16.7 million in cash and no […]
April 17, 2026 1:12pm
Amid increased demand for advanced collision-avoidance systems as rail networks grow more complex, Rail Vision’s (NASDAQ: RVSN) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological response. “Rail Vision develops vision-based detection systems designed to improve railway safety and operational performance, offering real-time obstacle detection and situational awareness that align closely with evolving safety priorities across the […]
April 17, 2026 12:23pm
Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. […]
April 17, 2026 11:39am
Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of […]
April 17, 2026 11:10am
Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the […]
April 17, 2026 9:50am
Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug regimens targeting different biological pathways are delivering results that single agents cannot. […]
April 17, 2026 9:10am
HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized […]
April 16, 2026 9:30am
Datavault AI (NASDAQ: DVLT) a provider of data monetization, credentialing, digital engagement and real-world asset tokenization technologies, announced that the first sites of its quantum-ready high-performance computing GPU network are now live in New York and Philadelphia, with full commercial availability of its planned 48,000-GPU fleet expected in Q3 2026. The network, designed to operate outside the hyperscaler supply chain, will […]
April 16, 2026 9:30am
Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy, reinforcing the company’s focus on developing innovative treatments for serious […]
April 15, 2026 11:24am
Safe Pro Group (NASDAQ: SPAI), an AI-enabled defense and security solutions provider, announced it successfully completed a U.S. Army live fire exercise where its patented AI technology processed drone imagery at the edge to detect live scattered mines and deliver actionable intelligence to commanders. The exercise builds on a prior government contract and supports the rollout […]
April 15, 2026 11:10am
Polyrizon (NASDAQ: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor, generating approximately $3.5 million in gross proceeds. The transactions included the sale of 388,888 units or pre-funded units at a combined price of $9.00 per unit, consisting […]